文献速递白血病

急性髓系白血病亚型特异性NGS预后价值在强化化疗中的研究

Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.
PubMed 文献 · Am J Hematol · 2026-07-18

该研究分析了545例接受强化诱导化疗的新诊断急性髓系白血病患者,按亚型分组评估常规NGS数据的预后价值。中位随访49个月,记录341例异基因造血干细胞移植。结果显示不同亚型的完全缓解率和5年移植删失生存率差异显著,特定基因突变的预后意义主要局限于原发非CBF亚型。

要点

  • NGS预后评估应首先明确AML亚型,非原发AML中NGS价值有限。
  • 原发非CBF AML中,FLT3-ITD与更高CR/CRi相关,KRAS和TET2突变与更差生存相关。
  • 继发于MPN的AML预后极差,应与继发于MDS/MPN的AML区分。

核心结论

  • 强化化疗AML的预后判断应始于亚型分类,并认识到NGS在非原发AML中价值有限。
  • 继发于MPN的AML预后尤其差,应与继发于MDS-MDS/MPN的AML在预后上区分。

研究设计与样本

  • 回顾性系列分析2015-2025年Mayo Clinic的545例新诊断AML患者,中位年龄56岁,女性44%。
  • 所有患者接受以7+3为骨架的强化诱导化疗,中位随访49个月,记录341例(63%)异基因造血干细胞移植。

主要发现

  • 各亚型CR/CRi率分别为CBF 89%、原发非CBF 76%、继发MDS-MDS/MPN 64%、继发MPN 27%、治疗相关AML 78%(p<0.01)。
  • 5年移植删失生存率分别为CBF 68%、原发非CBF 57%、继发MDS-MDS/MPN 21%、继发MPN 0%、治疗相关AML 55%(p<0.01)。
  • 原发非CBF AML多变量分析中,不良核型(OR 1.9;p=0.04)预测较差CR/CRi,FLT3-ITD(OR 0.4;p<0.01)或NPM1突变/FLT3野生型(OR 0.1;p<0.01)预测较好CR/CRi。
  • 原发非CBF AML中,KRAS突变(HR 8.8;p<0.01)、TP53突变(HR 5.4;p<0.01)和TET2突变(HR 2.3;p=0.01)预测较差生存,NPM1突变/FLT3野生型(HR 0.3;p=0.01)预测较好生存。

关键数值与推荐

  • 完全缓解率(含或不含计数恢复)各亚型间差异显著(p<0.01)。
  • 5年移植删失生存率各亚型间差异显著(p<0.01)。
  • 原发非CBF AML中特定突变的风险比和比值比如上所述。

临床怎么用

  • 对强化化疗的AML患者,应先明确亚型再解读NGS预后意义。
  • 原发非CBF AML中可结合FLT3-ITD、NPM1、KRAS、TP53、TET2等突变进行风险分层。
  • 继发于MPN的AML应视为预后极差组,可能与继发于MDS-MDS/MPN的AML区分管理。

局限性

  • FLT3-ITD对CR/CRi的有利影响以及KRAS、TET2突变对生存的不利影响需额外研究确认。
  • 研究为单中心回顾性系列,结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We examined the prognostic value of routine NGS data in newly diagnosed acute myeloid leukemia (AML) treated with intensive (7 + 3 backbone) induction, specified by AML subtype. A contemporary (2015-2025) series of 545 Mayo Clinic patients (median age 56 years, females 44%) was considered. Median follow-up was 49 months with 341 (63%) allogeneic hematopoietic stem cell transplantations (AHSCT) recorded. AML subtypes included core-binding factor (CBF; N = 72; 13%), primary non-CBF (N = 403; 74%), post-myelodysplastic syndromes (MDS) or post-myelodysplastic/myeloproliferative neoplasms (post-MDS-MDS/MPN; N = 28; 5%), post-MPN (N = 15; 3%), and therapy-related (t-AML; N = 27; 5%). Corresponding complete remission rates, with/without count recovery (CR/CRi), were 89%, 76%, 64%, 27%, and 78% (p < 0.01) and 5-year transplant-censored survival rates 68%, 57%, 21%, 0%, and 55% (p < 0.01). In multivariable analyses, the prognostic value of specific mutations was mostly limited to primary non-CBF AML where adverse karyotype (OR 1.9; p = 0.04) predicted inferior and FLT3-ITD (OR 0.4; p < 0.01) or NPM1 MUT/FLT3 WT (OR 0.1; p < 0.01) superior CR/CRi while KRAS MUT (HR 8.8; p < 0.01), TP53 MUT (HR 5.4; p < 0.01), and TET2 MUT (HR 2.3; p = 0.01) predicted inferior and NPM1 MUT/FLT3 WT (HR 0.3; p = 0.01) superior survival. Prognostication in intensively-treated AML should start with subtype specification and recognition of the limited value of NGS in non-primary AML. Post-MPN AML is particularly associated with dismal outcomes and should be prognostically distinguished from post-MDS-MDS/MPN AML. In primary non-CBF AML, in addition to previously established risk factors, the favorable impact of FLT3-ITD on achieving CR/CRi and the unfavorable impact of KRAS MUT and TET2 MUT on transplant-censored survival were noted and require confirmation from additional studies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Bolarinwa A, Al-Kali A, Alkhateeb HB, et al. Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy. Am J Hematol. 2026. PMID: 42470254. doi:10.1002/ajh.70443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。